Live data · NADAC + Part D CY24 · reviewed daily

Naproxen (EC-NAPROXEN)

Nonsteroidal Anti-inflammatory Drug class · 17 generic manufacturers · 50 ANDAs filed at FDA.

First FDA approval2007-04-26
Generic availableYes · 17 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$57.0M in CY2024 Part D spend4.4M claims · 2.2M beneficiaries · 329 plans surveyed

Lowest NADAC
$0.044/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.047
Across all dosage forms in distribution.
Highest NADAC
$0.057
Range is tight.
Plans with PA
0 / 329
Zero PA friction across surveyed plans.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Naproxen used for?

Naproxen is tracked in Medicare Part D. Specific indication information is not available in our current dataset.

Is there a generic for Naproxen?

Yes. 50 ANDAs filed at FDA, 17 generic manufacturers currently shipping.

How much does my plan pay for Naproxen?

Across 329 Part D plans, Naproxen averages $0.047/unit (NADAC). Lowest available: $0.044/unit. Highest in distribution: $0.057/unit.

Is Naproxen on the FDA shortage list?

No. Naproxen is not currently on the FDA Drug Shortage Database.

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh15 Oct 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.